SEC Filing Summary: Amedica Corporation (8-K)
Business Context and Reporting Period
This Form 8-K was filed by Amedica Corporation on February 15, 2017, reporting events occurring on February 14, 2017. The filing addresses the company's status regarding continued listing on The Nasdaq Capital Market. Note: The request metadata references "Sintx Technologies, Inc.," but the filing text explicitly identifies the registrant as "Amedica Corporation."
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on regulatory compliance regarding stock listing standards.
Material Changes and Listing Status
- Non-Compliance: On August 17, 2016, Nasdaq notified the company that its common stock bid price had closed below the minimum $1.00 per share requirement for 30 consecutive trading days.
- Grace Period Extension: On February 14, 2017, Nasdaq granted an additional 180-day grace period to regain compliance, extending the deadline to August 14, 2017.
- Compliance Basis: The extension was granted because the company met all other listing requirements, including the market value of publicly held shares, and submitted a written notice of intent to cure the deficiency.
- Proposed Remedy: The company intends to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary.
Outlook, Risks, and Contingencies
- Delisting Risk: If the company fails to regain compliance by August 14, 2017, Nasdaq will provide written notification of delisting.
- Appeal Process: In the event of a delisting determination, the company may appeal to a NASDAQ Hearings Panel. The stock would remain listed pending the Panel's decision.
- Uncertainty: Management states there can be no assurance that an appeal to the Hearings Panel would be successful.
Investor Verification Checklist
- Verify the current bid price of Amedica Corporation's common stock to assess progress toward the $1.00 threshold.
- Monitor for announcements regarding the execution of a reverse stock split before the August 14, 2017 deadline.
- Review the attached press release (Exhibit 99.1) for additional management commentary on the delisting risk.
- Confirm whether the company has filed any subsequent 8-Ks regarding the outcome of the grace period or appeal processes.